分子伙伴和Orano Med修改协议,重点是针对癌症治疗的四个无线电-DARPin方案。 Molecular Partners and Orano Med modify agreement, focusing on four Radio-DARPin programs for targeted cancer therapy.
分子伙伴和Orano Med已经修改了共同开发协议,将重点放在四个无线电-DARPin节目上,允许每家公司将两个节目商业化。 Molecular Partners and Orano Med have modified their co-development agreement to focus on four Radio-DARPin programs, allowing each company to commercialize two programs. 分子伙伴将领导DLL3目标候选人MP0712的商业化,预计将在2025年进行人类先期研究,等待监管批准。 Molecular Partners will lead the commercialization of the DLL3-targeting candidate MP0712, with first-in-human studies expected in 2025, pending regulatory approval. DARPIN电台平台旨在通过高效的药物发现和减少非目标效果,加强有针对性的癌症治疗。 The Radio-DARPin platform aims to enhance targeted cancer therapy through efficient drug discovery and reduced off-target effects.